Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Abnormally high serum levels of Lp(a) in patients with CVD and VD seemed to be due to specific increases in low-molecular-weight apolipoprotein(a) isoforms in Lp(a).
|
10765043 |
2000 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Lipoprotein (a) and 10-year Cardiovascular Disease Incidence in Apparently Healthy Individuals: A Sex-based Sensitivity Analysis from ATTICA Cohort Study.
|
31185726 |
2019 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Several lipoprotein(a)-lowering therapies are currently being developed with the long-term goal of reducing cardiovascular disease and mortality; however, the relationship between lipoprotein(a) and mortality is unclear.
|
30608559 |
2019 |
Cardiovascular Diseases
|
0.500 |
AlteredExpression
|
group |
BEFREE |
The purpose of this study was to investigate CHD or cardiovascular disease (CVD) risk scores with cholesterol levels of six fractionated lipoprotein classes {high-density lipoprotein [HDL], low-density lipoprotein [LDL], IDL, VLDL, CM including CM remnant, and lipoprotein (a) [Lp (a)]} in Japanese healthy men.
|
28025448 |
2017 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
In this regard, the greater CVD in Blacks than Whites have been partly attributed to other non-traditional CVD risk factors, such as subclinical inflammation (C-reactive protein), homocysteine, increased low-density lipoprotein oxidation, lipoprotein a, adiponectin, and plasminogen activator inhibitor-1, etc.
|
28912752 |
2017 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
New and known genetic determinants of plasma levels of LDL cholesterol, lipoprotein(a), and triglyceride-rich lipoproteins are concordant with both the magnitude and direction of the expected risk of cardiovascular disease, whereas this is unclear for HDL cholesterol.
|
21358543 |
2011 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Lipoprotein(a) as a key target in combined therapeutic approaches for cardiovascular disease.
|
31530423 |
2019 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
CTD_human |
Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy.
|
18775538 |
2009 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Lipoprotein(a) [Lp(a)] has been considered to be a predictor of premature coronary heart disease and other cardiovascular diseases.
|
10098351 |
1999 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
To examine the relations between genetic loci, plasma lipoprotein(a) [Lp(a)] levels, and cardiovascular disease (CVD) risk among diabetic patients and compare with the observations in the general population.
|
21900290 |
2012 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Increased levels of lipoprotein (a) [Lp(a)] have been considered an independent risk factor for cardiovascular disease, but the mechanism behind this relationship is not completely understood.
|
9580386 |
1998 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
1.Elevated plasma lipoprotein (a) (Lp(a)) concentrations have been correlated with an increased risk of premature cardiovascular disease.
|
10225140 |
1999 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Robust epidemiologic and genetic studies have solidified the role of lipoprotein (a) [Lp(a)] as an independent and causal risk factor for cardiovascular disease.
|
25736345 |
2015 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
High lipoprotein(a) (Lp(a)) serum concentrations and the underlying apolipoprotein(a) (apo(a)) phenotypes are risk factors for cardiovascular disease in the general population as well as in patients with renal disease.
|
10616846 |
2000 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Elevated low-density lipoprotein cholesterol and/or lipoprotein(a) are established risk factors for cardiovascular disease (CVD).
|
30799420 |
2019 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Lipoprotein(a) (Lp[a]) is proatherosclerotic and prothrombotic, causally related to coronary disease, and associated with other cardiovascular diseases.
|
29246963 |
2017 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
The objective was to investigate the effects of isolated soy isoflavones on metabolic biomarkers of cardiovascular disease risk, including plasma total, HDL, and LDL cholesterol; triacylglycerols; lipoprotein(a); the percentage of small dense LDL; glucose; nonesterified fatty acids; insulin; and the homeostasis model assessment of insulin resistance.
|
16522905 |
2006 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Lipoprotein(a) in American Indians is low and not independently associated with cardiovascular disease. The Strong Heart Study.
|
11880218 |
2002 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Although lipoprotein(a) [Lp(a)] is associated with incident cardiovascular disease (CVD), its contribution to prediction remains controversial.
|
30012322 |
2018 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions.
|
14578310 |
2003 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Family history of early cardiovascular disease in children with moderate to severe hypercholesterolemia: relationship to lipoprotein (a) and low-density lipoprotein cholesterol levels.
|
10072255 |
1999 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Increased plasma level of lipoprotein(a) (Lpa) is a risk factor of cardiovascular diseases.
|
30071823 |
2018 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Therefore, in the evaluation of a fully automated, particle-enhanced turbidimetric immunoassay for the measurement of lipoprotein(a) we have determined its reference interval in the Spanish population, an area with the lowest incidence of cardiovascular disease in Europe.
|
12633762 |
2003 |
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
LHGDN |
ApolipoproteinA1-75 G/A (M1-) polymorphism and lipoprotein(a); anti- vs. pro-Atherogenic properties.
|
17683612 |
2007 |
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Lipoprotein(a) [Lp(a)] is an independent CVD risk factor where plasma levels are determined by the apolipoprotein(a) [apo(a)] gene, which contains inflammatory response elements.
|
18252779 |
2008 |